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AbstrACt
Objective To measure health-related quality of life 
(HRQoL) and well-being in older people with end-stage 
kidney disease (ESKD) and to determine the association 
between treatment type and sociodemographic 
characteristics on these outcome measures. In addition, 
to assess the convergent validity between the HRQoL and 
well-being measure and their feasibility and acceptability 
in this population.
Design Prospective cross-sectional study.
setting Three renal units in the UK and Australia.
Participants 129 patients with ESKD managed with 
dialysis or with an estimated glomerular filtration 
≤10 mL/min/1.73 m2 and managed with comprehensive 
conservative, non-dialytic care.
Outcome measures HRQoL and well-being were 
assessed using Short-Form six dimensions (SF-6D, 0–1 
scale); Kidney Disease Quality of Life (KDQOL-36) (0–100 
scale) and Investigating Choice Experiments Capability 
Measure-Older people (ICECAP-O, 0–1 scale). Linear 
regression assessed associations between treatment, 
HRQoL and well-being. Pearson’s correlation coefficient 
assessed convergent validity between instruments.
results Median age of 81 years (IQR 78–85), 65% males; 
83 (64%) were managed with dialysis and 46 (36%) with 
conservative care. When adjusted for treatment type and 
sociodemographic variables, those managed on dialysis 
reported lower mean SF-6D utility (−0.05, 95% CI −0.12 to 
0.01); lower KDQOL Physical Component Summary score 
(−3.17, 95% CI −7.61 to 1.27); lower Mental Component 
Summary score (−2.41, 95% CI −7.66 to 2.84); lower 
quality of life due to burden (−28.59, 95% CI −41.77 to 
−15.42); symptoms (−5.93, 95% CI −14.61 to 2.73) and 
effects of kidney disease (−16.49, 95% CI −25.98 to 
−6.99) and lower overall ICECAP-O well-being (−0.07, 
95% CI −0.16 to 0.02) than those managed conservatively. 
Correlation between ICECAP-O well-being and SF-6D utility 
scores was strong overall, 0.65 (p<0.001), but weak to 
moderate at domain level.
Conclusions Older people on dialysis report significantly 
higher burden and effects of kidney disease than those 
on conservative care. Lower HRQoL and well-being may 
be associated with dialysis treatment and should inform 
shared decision-making about treatment options.
trial registration number UK (IRAS project ID: 
134360andREC reference 14/LO/0291) and Australia 
(R20140203 HREC/14/RAH/36).
IntrODuCtIOn
Comprehensive conservative care services 
were developed for people with end-stage 
kidney disease (ESKD) in the UK and 
Australia following the substantial increase 
in the number of older people aged ≥75 
years being referred to nephrologists for 
dialysis.1 Comprehensive conservative 
care includes interventions to delay the 
progression of kidney disease and minimise 
strengths and limitations of this study
 ► The strengths of our study include a prospective as-
sessment of health-related quality of life (HRQoL) in 
people over 75 years of age and the use of a novel 
measure to value well-being.
 ► This information is essential for doctors to discuss 
the relative benefits of dialysis compared with con-
servative care.
 ► The limitation of this study is that the sample size 
may not have been sufficient to detect a statistically 
significant difference in mean scores if one existed.
 ► We did not have complete data on patient’s comor-
bid conditions that may have impacted our ability to 
explore the associations between comorbid condi-
tions and HRQoL or well-being.
 ► Considering the cross-sectional nature of the data, 
we were unable to analyse any changes relating to 
individuals’ HRQoL or well-being over time, which 
might be captured in a longitudinal study.
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complications, as well as detailed communication, shared 
decision-making, advance care planning and psychologic 
and family support, but does not include dialysis.2 For 
older patients who often have high levels of comorbidity 
(such as diabetes and heart disease) and poor functional 
status, the survival advantage of dialysis may be limited 
and comprehensive conservative management may 
be considered; however, robust comparative evidence 
remains minimal.2 Considerations such as symptoms, 
quality of life and hospital-free days are sometimes more 
important for patients and families, than expected length 
of survival.2 
Traditionally, economists attempt to assist resource allo-
cation decisions by focusing on measuring and valuing 
health (in its broadest sense), using health-related quality 
of life (HRQoL) measures and survival, in particular 
combined in the quality-adjusted life year (QALY).3 In 
QALY calculations, values (often referred to as utility 
scores) are assigned to different health states, which allows 
the quantification of health gains comprising both length 
and quality of life gains from medical interventions.3 4 
Utilities are preference weights, where preference can be 
equated with value or desirability.5 6 The QALY is then 
calculated by combining the length of survival and the 
utility weights.
However, many healthcare interventions may impact 
more broadly on quality of life (assumed to encompass 
the broad range of factors that are important to people 
in living their lives) rather than just health (which centres 
on physical and mental health).3 These broad factors 
could be related to health and non-health factors that may 
impact the overall quality of life of a patient.4 Measures 
that look only at health in assessing the impact of these 
interventions would be very likely to underestimate this 
impact.3 7
Dialysis has a large impact on the quality of life of 
both patients and their families; however, traditional 
HRQoL measures, such as the Short Form 36 (SF-36) 
and Kidney Disease Quality of Life (KDQOL-36) surveys 
may be too narrowly focused to detect all of the critical 
aspects of dialysis that increase or decrease an individu-
al’s quality of life.8 KDQOL-36 is a short-form question-
naire that includes the SF-12, a generic quality of life 
questionnaire,9 10 plus disease-specific domains including 
the burden of kidney disease, symptoms/problems of 
kidney disease and effects of kidney disease. For this 
purpose, broader HRQoL measures, often named well-
being measures, could be used to capture more facets of 
peoples’ lives than health status alone.4
New instruments have been developed that provide 
information across health and social care, rather than 
just across health.3 The recently developed Investigating 
Choice Experiments Capability Measure (ICECAP) family 
of instruments have been designed to incorporate such 
dimensions.11 These instruments have their theoretical 
grounding in Amartya Sen’s work on the relationships 
between functioning and capability.11 12 They seek to 
measure a conceptually different evaluative space through 
a focus on capabilities: that is, what a person is able to do 
and who they are able to be, rather than on functioning: 
what a person actually does and who they become.13 Capa-
bilities refer to the potential to achieve certain states and 
perform certain actions.4 Having the capability to live life 
the way one desires is obviously important, also to older 
people, and reduction of this capability limits their well-
being.4 14 15 The ICECAP-O instrument was specifically 
developed to measure capability in older people. There 
is little research on how the ICECAP-O is related to other 
conceptualisations of well-being and the relationships 
between the ICECAP-O and measures of health (physical, 
psychological and social) remain underexplored.16
The aims of the study were to measure HRQoL using 
SF-12 questionnaire, KDQoL using KDQOL-36 ques-
tionnaire and well-being using ICECAP-O questionnaire 
(1) to determine the association between treatment type 
and sociodemographic characteristics on these outcome 
measures; (2) to assess the convergent validity between 
the ICECAP-O well-being and the SF-6D utility (derived 
from SF-12 questionnaire) and (3) to assess the feasibility 
and acceptability of questionnaires in older patients with 
ESKD.
MAterIAls AnD MethODs
study design
We conducted a cross-sectional study of patients with 
ESKD treated with dialysis or comprehensive conserva-
tive care in the UK and Australia between 2014 and 2017. 
The study was performed in accordance with the Austra-
lian National Statement on Ethical Conduct in Human 
Research (2007) and relevant guidance in the UK. The 
study was reported using Strengthening the Reporting 
of Observational Studies in Epidemiology guidelines for 
observational studies (online supplementary item S1).17 
Eligible subjects were fully informed about the purpose, 
benefits and risks of the study and signed an approved 
participant consent form.
setting and participants
The study was undertaken at three renal units in the UK 
and Australia. Included were males and females aged ≥75 
years with ESKD, managed with dialysis (facility haemodi-
alysis, home haemodialysis and peritoneal dialysis) or with 
an estimated glomerular filtration ≤10 mL/min/1.73 m2 
and managed with comprehensive conservative, non-di-
alytic care. The exclusion criteria comprised cognitive 
impairment; patients unable to read English and patients 
who were legally blind. To reduce selection bias, nephrol-
ogists and clinical nurses in each participating renal unit 
reviewed their clinic lists for all patients who met the eligi-
bility criteria.
sample size calculation
As per the study protocol, a sample size of 194 patients 
(97 on dialysis, 97 on comprehensive conservative care) 
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was calculated to detect a mean difference of 0.05 in the 
outcomes with 80% power and 95% confidence.
Patient and public involvement
The research question was developed from prior quali-
tative work with people with ESKD and their carers.18–20 
Patients were not directly involved in the design of 
this research study. Patients and their caregivers were 
informed of the study and invited to participate by the 
renal unit’s research nurses. Participants were provided 
with an information sheet and consent form for them to 
read. If they were interested in participating they were 
asked to sign the consent form and then were provided 
with two surveys contained in the one booklet (the 
ICECAP-O survey and the standard KDQOL-36) while 
at their renal clinic. Patients and their caregivers were 
assured that participation was voluntary that they did 
not have to participate and that their decision either way 
would not affect their clinical care.
Outcomes and variables
The key outcomes were SF-6D utilities derived from the 
SF-12 questions, KDQOL scores from the KDQOL-36 
questions and ICECAP-O capability index derived from 
the ICECAP-O questions. Other outcomes were conver-
gent validity between ICECAP-O well-being and the 
SF-6D utility instrument measured using the Pearson’s 
correlation coefficient; the feasibility and acceptability 
of the ICECAP-O and SF-12 questionnaires, assessed 
by response rate and specific items asking the patient 
whether the questionnaire was easy to complete and 
whether it covered questions important to their quality of 
life and well-being.
Data sources/measurement
All eligible patients were invited to complete the 
KDQOL-36 (online supplementary item S2) and the 
five-question ICECAP-O questionnaire (online supple-
mentary item S3) while at their renal clinic. Relevant 
sociodemographic details such as age, sex, country, educa-
tional attainment, private health insurance and questions 
assessing feasibility and acceptability of the ICECAP-O 
and SF-12 questionnaire were collected (Item S4). Kidney 
treatment type (facility haemodialysis, home haemodial-
ysis, peritoneal dialysis and comprehensive conservative 
care), dialysis status (if currently on dialysis, and time of 
initiation) and renal transplant status were documented.
hrQol questionnaire
The KDQOL-36 has 36 items: the SF-12 version 1 and 
another 24 kidney-specific items.21 The SF-12 responses 
on the KDQOL-36 were transformed into HRQoL weights, 
known as utilities, using a published SF-6D algorithm.22 
The SF-6D is a generic preference-based single measure 
of health used to generate utilities from six domains: 
physical, role, social, pain, mental and vital (online 
supplementary item S5). The SF-6D utilities generated 
are measured on a 0 (death) to 1 (full health) scale and 
were reported with mean and SDs using UK population 
values.22–24
The SF-12 section of KDQOL-36 also yields Physical 
Component Summary (PCS) and Mental Component 
Summary (MCS) scores, both of which are scored on a 
T-score metric (mean=50, SD=10, for the US general 
population).21 25 The three kidney-specific scales assess 
burden of kidney disease, symptoms of kidney disease and 
effects of kidney disease. Each of these scales is scored 
by transforming all items to a 0–100 possible range and 
averaging across the items on each scale to create scale 
scores.21 KDQOL-36 items are all scaled so that higher 
scores indicate better HRQoL.21 26
Well-being questionnaire
The ICECAP-O questionnaire measures capabilities and 
covers five domains of well-being, including attachment 
(love and friendship), security (thinking about the future 
without concern), role (doing things that make you feel 
valued), enjoyment (enjoyment and pleasure) and control 
(independence).27 It has four-level response options, 
representing four levels of capability: none, a little, a lot 
and all. The responses on the ICECAP-O questions were 
transformed to a ICECAP-O capability index ranging 
from 0 (no capability) to 1 (full capability) and presented 
with mean and SDs using UK population weights.3
Quantitative variables
The SF-6D utilities, KDQOL scores, ICECAP-O capability 
index and patients’ age were treated as continuous, while 
patients’ sex, treatment type (dialysis, conservative care), 
education (some high school or lower levels, completed 
high school or higher levels), private health insurance 
(yes, no) and country (UK, Australia) were analysed as 
categorical variables. Age was also additionally dichoto-
mised (less than or equal to vs greater than the median 
age (81 years)).
statistical methods
The analysis of data involved descriptive statistics 
assessing proportions and mean values of the SF-6D util-
ities, PCS, MCS, Burden of Kidney Disease, Symptoms of 
Kidney Disease, Effects of Kidney Disease scores and the 
ICECAP-O capability index for the entire cohort. Hypoth-
esis testing with a two-tailed Student’s t-test was used to 
detect differences in the mean values of SF-6D utilities, 
KDQOL-36 scores and ICECAP-O capability index for 
patients’ treatment type and sociodemographic charac-
teristics. We hypothesised that HRQoL and well-being 
measures in each treatment group would be equivalent.
Linear regression with multivariable models was under-
taken to determine the association between treatment 
type and patient characteristics on SF-6D utilities, KDQOL 
scores and ICECAP-O capability index. In the multivari-
able linear regression, age, sex, treatment type, educa-
tion, private health insurance and country were included 
as covariates on the basis of a priori knowledge of their 
associations with the HRQoL and well-being measures.
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Pearson’s correlation coefficient was used to deter-
mine the convergent validity of the ICECAP-O well-being 
with the SF-6D utility instrument. The correlations were 
assessed for the overall ICECAP-O and SF-6D utility scores 
and their domains. We hypothesised, moderate to strong 
positive correlations because both these instruments 
measures some similar facets of quality of life. Correla-
tions above 0.5 were considered strong, between 0.3 and 
0.5 as moderate and below 0.3 as weak.16
Complete case analysis was performed for all outcomes. 
All statistical analyses were performed with SAS V.9.4. A 
p value of <0.05 was considered statistically significant.
results
A total of 129 patients were recruited, including 83 (64%) 
managed with dialysis and 46 (36%) patients managed 
with comprehensive conservative care. The majority of 
conservatively treated patients were from Australia (n=37) 
and most treated with dialysis were from the UK (n=58). 
Overall, 65% were male, and the median age of the entire 
cohort was 81 years (IQR 78–85). Patient characteristics 
are shown in table 1.
hrQol sF-6D utilities
Of 129 patients, the mean utility for 116 patients with 
complete data was 0.62 (SD 0.14) (n=13 missing values). 
The mean SF-6D utilities for the dialysis group were 0.61 
(SD 0.13) and 0.65 (SD 0.15) for the conservative care 
group (online supplementary table S1). The ‘vitality’ 
domain reported the highest average score and was 
responsible for the highest decrement in utilities in both 
treatment groups (online supplementary table S2).
The mean SF-6D utilities were 0.07 (SD 0.14) lower for 
females than for males (p=0.006); 0.06 (SD 0.14) lower 
for patients residing in the UK compared with those 
residing in Australia (p=0.03) and 0.07 (SD 0.14) lower for 
patients without a private health insurance compared to 
patients with a private health insurance (p=0.03) (online 
supplementary table S1). When adjusted for all variables, 
the mean SF-6D utilities were 0.09 lower for females 
compared with males (95% lower CI=−0.14 and upper 
Table 1 Patients characteristics according to treatment group
Patient Characteristics 
Dialysis Conservative Care Total 
n=83 n=46 n=129
n (%) n (%) n (%) 
Dialysis
  Facility haemodialysis 68 (82 – 68 (53) 
  Home haemodialysis 2 (2) –  2 (2) 
  Peritoneal dialysis 13 (16) –  13 (10) 
Median age (years) 81 (78–84) 83 (81–87)  81 (78–85) 
Age group
  ≤81 years 50 (60) 19 (41)  69 (53) 
  >81 years 33 (40) 27 (59)  60 (47) 
Sex
  Males 57 (69) 27 (59) 84 (65)
  Females 26 (31) 19 (41) 45 (35)
Country
  UK 58 (70) 9 (20) 67 (52)
  Australia 25 (30) 37 (80) 62 (48)
Education
  Primary school 26 (31) 19 (41) 45 (35)
  Some high school 35 (42) 17 (37) 52 (40)
  Completed high school 8 (10) 3 (7) 11 (9)
  Completed diploma 6 (7) 3 (7) 9 (7)
  Completed university degree 7 (8) 3 (7) 10 (8)
Private health insurance
  Yes 15 (18) 14 (30) 29 (22)
  No 65 (78) 29 (63) 94 (73)
  Unknown 1 (1) 1 (2) 2 (2)
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CI=−0.03, p=0.002). There was no significant difference 
in the mean utilities observed between two treatments 
when adjusted for other variables (table 2).
KDQOl scores
The mean KDQOL scores on the five domains for 
patients with complete data were as follows: PCS score of 
32.41 (n=115, SD 9.68); MCS score of 47.25 (n=115, SD 
11.34); Burden of Kidney Disease score of 44.46 (n=127, 
SD 31.28); Symptom/Problems of Kidney Disease score 
of 72.78 (n=125, SD 19.03) and Effects of Kidney Disease 
score of 70.24 (n=127, SD 22.35).
In univariate analysis, the PCS score was 5.46 points 
lower in females than males (p=0.004) (ie, lower phys-
ical health); the MCS score was 4.63 points lower in 
Australian versus UK patients (p=0.03) (ie, lower mental 
health) (online supplementary table S1 and table S3). 
The Burden of Kidney Disease score was 28.12 points 
lower in the dialysis group than the conservative care 
group (p<0.001) (indicating a higher burden of disease 
and lower quality of life) (figures 1 and 2); 14.06 points 
lower in UK versus Australian patients (p=0.01) (indi-
cating higher burden of disease); 13.70 points lower 
in patients without private health insurance compared 
with those with private health insurance (p=0.04) (indi-
cating a higher burden of disease). The Effects of Kidney 
Disease score was 17.11 points lower in the dialysis group 
compared with the conservative care group (p<0.001) 
(indicating higher effects of the disease and lower quality 
of life) (figures 3 and 4); 8.35 points lower in UK versus 
Australian patients (p=0.03) (indicating higher effects of 
the disease).
The dialysis group reported a higher MCS score (47.67 
vs 46.56), indicating marginally better mental health than 
the conservative care group (online supplementary table 
S2).
When adjusted for other variables, the mean score 
for the burden of kidney disease subscale was 28.59 
lower (ie, more burdensome) for patients on dialysis 
compared with patients on conservative care (p<0.001) 
Table 2 Adjusted difference in SF-6D utilities, KDQOL-36 scores and ICECAP-O capability index for dialysis compared with 
conservative care (fully adjusted)
Differences* 95% lower CI 95% upper CI P value
SF-6D utilities −0.05 −0.12 0.01 0.12
KDQOL—PCS −3.17 −7.61 1.27 0.16
KDQOL—MCS −2.41 −7.66 2.84 0.37
KDQOL—burden of disease −28.59 −41.77 −15.42 <0.001†
KDQOL—symptoms of disease −5.93 −14.61 2.73 0.18
KDQOL—effects of disease −16.49 −25.98 −6.99 <0.001†
ICECAP-O capability index −0.07 −0.16 0.02 0.12
*Difference in scores adjusted for age, gender, country, education and health insurance status.
†P<0.001, statistical significance.
ICECAP-O, Investigating Choice Experiments Capability Measure- Older people; KDQOL-36, Kidney Disease Quality of Life with 36 items; 
MCS, mental component summary; PCS, physical component summary; SF-6D, Short-Form six dimensions.
Figure 1 Kidney Disease Quality of Life-36 Burden of 
Kidney Disease score for dialysis group (n=83). A higher 
score indicates lower burden of disease and better quality of 
life.
Figure 2 Kidney Disease Quality of Life-36 Burden of 
Kidney Disease score for conservative care group (n=44). A 
higher score indicates lower burden of disease and better 
quality of life.
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(table 2). The mean score for effects of kidney disease 
when adjusted for all the other variables, was 16.49 lower 
(ie, higher disease-related effects) for patients on dialysis 
compared with patients on comprehensive conservative 
care (p<0.001) (table 2). Adjusted scores were lower but 
not statistically, significantly different for PCS, MCS and 
symptoms of kidney disease between the two treatment 
groups.
ICeCAP-O capability index
The mean ICECAP-O capability index for 126 patients with 
complete data was 0.72 (SD 0.19) (n=3 missing values). In 
the dialysis group, the mean capability index was 0.71 (SD 
0.19) and 0.76 (SD 0.20) for the conservative care group 
(online supplementary table S1), but not significantly 
different. Overall, the dialysis treatment group reported a 
lower well-being score on all five domains compared with 
the conservative care group. The ‘attachment’ domain 
showed the highest average score and was responsible for 
the highest contribution to capabilities in both treatment 
groups (online supplementary table S2). When adjusted 
for other variables, there were no significant differences 
in the mean capability index observed between the two 
treatments (table 2).
Convergent validity
For 114 observations, the overall SF-6D utilities and the 
pain domain of the SF-6D were strongly correlated with 
the overall ICECAP-O capability index with a Pearson’s 
coefficient of 0.65 (p<0.001) and 0.56 (p<0.001), respec-
tively. At the domain level, the role and control domains 
of the ICECAP-O questionnaire were strongly correlated 
with the pain domain of the SF-6D, with a Pearson’s 
coefficient of 0.51 (p<0.001) and 0.53 (p<0.001), respec-
tively. All other domains of the ICECAP-O were weakly 
or moderately correlated with SF-6D domains, values 
ranging from 0.02 to 0.49 (table 3).
Feasibility and acceptability
One hundred and fifteen of 129 patients completed the 
questionnaire, with 14 patients missing items for the 
ICECAP-O and 10 patients missing items for the SF-12. 
Overall, patients found both questionnaires easy to use 
and relevant to assessing their well-being. They responded 
with an average score of 1.78 out of 5 (1=strongly agree, 
5=completely disagree) on questions assessing ease of use 
and with an average score 1.77 and 1.79 out of 5 on the 
questions assessing the relevance of ICECAP-O and the 
SF-12 questions, respectively.
DIsCussIOn
This prospective cross-sectional study determined the 
mean SF-6D utilities, KDQOL scores and ICECAP-O capa-
bility index for patients with ESKD according to treatment 
and sociodemographic variables. Our findings suggest 
females compared with males, patients residing in the UK 
compared with those residing in Australia and patients 
without private health insurance compared with those 
with private health insurance have significantly lower 
SF-6D utilities. However, when adjusted for the other 
variables, only females reported significantly lower utili-
ties compared with males. Furthermore, the study deter-
mined the convergent validity between the ICECAP-O 
well-being and SF-6D utility instrument and assessed the 
feasibility and acceptability of the ICECAP-O well-being 
and SF-12 questionnaire in older people with ESKD.
The dialysis group reported 0.05 lower SF-6D utilities 
compared with the conservative care group reflecting 
a potentially clinically meaningful difference related 
to treatment; however, this difference was not statisti-
cally significant. Meaningful differences or the minimal 
important difference (MID) in utility-based HRQoL 
reported in 11 studies using the SF-6D utilities ranged from 
0.011 to 0.097, with a mean MID of 0.041.28 It is therefore 
likely our study has detected a meaningful difference. In 
Figure 3 Kidney Disease Quality of Life-36 Effects of Kidney 
Disease score for dialysis group (n=82). A higher score 
indicates lower effects of disease and better quality of life.
Figure 4 Kidney Disease Quality of Life-36 Effects of Kidney 
Disease score for conservative care group (n=45). A higher 
score indicates lower effects of disease and better quality of 
life.
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addition, a 0.05 difference in ICECAP-O well-being for 
dialysis patients may also represent a clinically mean-
ingful difference; however, MIDs for ICECAP-O have not 
yet been published. Similarly, the KDQOL-36 instrument 
identified a higher burden of disease and greater effects 
of the disease for those on dialysis. This finding needs to 
be explored further in a larger sample size to investigate 
the potential detrimental effects of dialysis on HRQoL.
In our study, with the exception of a strong correlation 
between the ‘control’ and ‘role’ domain of the ICECAP-O 
with the ‘pain’ domain on the SF-6D, most of the 
ICECAP-O domains were found to have weak to moderate 
correlations with the SF-6D corresponding domains. This 
indicates that the newly developed capability instrument 
does measure different aspects of quality of life or well-
being and offers additional information when compared 
with measures of health, such as the SF-6D used in the 
conventional QALY approach. In addition, we observed 
a higher score for the feasibility and acceptability of the 
ICECAP-O questions indicating it to be acceptable and as 
relevant as SF-12 (an established HRQoL measure).
There is debate in the health economics literature 
concerning the ways to apply the capability approach in 
economic evaluations with some suggesting that QALYs 
alone are adequate, while others argue this approach 
is too narrow and that direct measures of capability or 
well-being provide a more extensive application of Sen’s 
paradigm.29 Capability is empirically distinct from func-
tioning and the content of capability instruments is not 
subsumed by the content of instruments used to capture 
changes in HRQoL for QALYs.29
Health economic analyses would benefit from the inclu-
sion of individual capability measures; whether the focus 
should be only on people’s achievements—their ‘func-
tioning’—or people’s capability to achieve is contested.29 
Sen’s example of the fasting man versus the starving man 
serves as a key example for focusing on capability: two 
people, one of whom is starving and the other, who is 
fasting, have comparable functioning in terms of nourish-
ment, but their capabilities to be nourished are notably 
different.29 The argument is that focusing on functioning 
alone would miss important distinctions, such as differ-
ences in freedom and choice between individuals.29
There are some limitations to this study. First, we were 
only able to recruit 129 of the 194 patients outlined in 
the protocol sample size, as some of the study sites were 
unable to participate. Hence, the sample size may not 
have been sufficient to detect a statistically significant 
difference in mean scores if one existed. Second, our 
observational study of older patients with ESKD may not 
have perfectly matched the two groups with respect to 
co-morbid conditions or rate of renal decline. We did not 
have complete data on comorbidities and this may have 
impacted our ability to explore the associations between 
treatment type, HRQoL or well-being. Third, considering 
the cross-sectional nature of the data, we were unable 
to analyse any changes relating to individuals’ HRQoL 
or well-being over time, which might be captured in a 
longitudinal study. The strengths of our study include a 
prospective assessment of HRQoL in people over 75 years 
of age and the use of a novel measure to value well-being. 
This information is essential for doctors to discuss the 
relative benefits of dialysis compared with conservative 
care.
In conclusion, we observed lower quality of life and 
well-being for older patients with ESKD managed on 
dialysis compared with comprehensive conservative care. 
Furthermore, measuring well-being using a capability 
index provides additional insights into the impact of dial-
ysis on older people than HRQoL measurement alone 
and has potential to improve the economic evaluation of 
treatment for ESKD.
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